These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31563021)

  • 1. Evaluation of drug candidature: In silico ADMET, binding interactions with CDK7 and normal cell line studies of potentially anti-breast cancer enamidines.
    Bansode P; Anantacharya R; Dhanavade M; Kamble S; Barale S; Sonawane K; Satyanarayan ND; Rashinkar G
    Comput Biol Chem; 2019 Dec; 83():107124. PubMed ID: 31563021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, Biological Evaluation and In Silico Studies of Certain Oxindole-Indole Conjugates as Anticancer CDK Inhibitors.
    Al-Warhi T; El Kerdawy AM; Aljaeed N; Ismael OE; Ayyad RR; Eldehna WM; Abdel-Aziz HA; Al-Ansary GH
    Molecules; 2020 Apr; 25(9):. PubMed ID: 32349307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
    Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
    Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel potent CDK7 inhibitors.
    Zhang H; Lin G; Jia S; Wu J; Zhang Y; Tao Y; Huang W; Song M; Ding K; Ma D; Fan M
    Bioorg Chem; 2024 Jul; 148():107456. PubMed ID: 38761706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
    Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
    Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of bivalent small molecule degraders of cyclin-dependent kinase 7 (CDK7).
    Ji W; Du G; Jiang J; Lu W; Mills CE; Yuan L; Jiang F; He Z; Bradshaw GA; Chung M; Jiang Z; Byun WS; Hinshaw SM; Zhang T; Gray NS
    Eur J Med Chem; 2024 Oct; 276():116613. PubMed ID: 39004018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
    Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis of quercetin derivatives as cytotoxic against breast cancer MCF-7 cell line
    Khan MR; Khan MA; Ahmad I; Ahmed J; Ahmed H; Mubeen I; Awan B; Ullah F
    Future Med Chem; 2024; 16(17):1749-1759. PubMed ID: 39101595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
    Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
    Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
    Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
    Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
    Wang M; Wang T; Zhang X; Wu X; Jiang S
    Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
    Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
    Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.
    Sabt A; Eldehna WM; Al-Warhi T; Alotaibi OJ; Elaasser MM; Suliman H; Abdel-Aziz HA
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1616-1630. PubMed ID: 32781872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological explorations of eco-friendly amide substituted (Z)-β-enaminones as anti-breast cancer drugs.
    Subramamiam P; Ramasubbu C; Athiramu S; Arumugam S; Alagumuthu M
    Arch Pharm (Weinheim); 2019 Jan; 352(1):e1800244. PubMed ID: 30515835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer.
    Attia YM; Shouman SA; Salama SA; Ivan C; Elsayed AM; Amero P; Rodriguez-Aguayo C; Lopez-Berestein G
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.